Scott Tykodi, MD, PhD, on Results from the KEYNOTE-427 Trial

Video

The Seattle Cancer Care Alliance Expert offered background on the first-line use of pembrolizumab monotherapy in advanced clear cell renal cell carcinoma.

Transcription:

Well, the Keynote study, you know, it started a few years ago, the primary clinical outcomes have been presented previously. But at the time it was conceived and enrolled, there was no data set for frontline, PD-1 or PD-L1 as monotherapy for renal cell carcinoma. So judging how much that's bringing to the table versus what's being added by the various doublets that are now standard of therapy was very helpful insight.

It's certainly the case in clinic you encounter patients that are elderly, they're frail, you're concerned about the toxicity of whatever therapy you're offering. And I certainly have some patients where I've started them on PD-1 a lot of therapy and held back either it'd be lymphoma or held back the exit nip doublet component to see how they fared and make sure they held up okay. So having some reference data set to know what you're getting into and what you can counsel a patient on the likely success. Starting off with just a single drug is extremely helpful.

And then pembrolizumab is moved into the Agilent space. And so having a reference data set as the monotherapy experience in the metastatic setting to know that the drug is active and feeling confident it's rational to pursue the adjuvant treatment protocol. So I think it has a lot of merits granted that pembrolizumab monotherapy doesn't have a formal FDA approval, but it is approved of course in combination with axitinib and then leaves it to the treating physician judgment about how to manage the axitinib component. So it is certainly available to us clinically to use now in our routine clinical population.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Related Content